Wire · opportunities
US FDA Approves Sanofi's Wearable Injector Form of Blood Cancer Drug
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 July 2026 · Fusion42 review
The US FDA has approved Sarclisa Escena, Sanofi's wearable subcutaneous injector form of a multiple myeloma drug, replacing intravenous infusions and reducing patient time in infusion centres. The approval marks a regulatory win for Sanofi's new leadership as it diversifies beyond its dependency on asthma drug Dupixent.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you make wearable injectors, on-body delivery devices, or infusion centre software, Sanofi just proved the market will pay for convenience over IV. Every oncology drug with repeat dosing is now a candidate for this form factor—call the top 20 pharma companies this week.
◆ Coverage
1 source · 10 Jul 2026
◆ Related on Wire
◆ Topics